Cases & Deals

  • Celgene prevails in Apotex and Cipla IPR challenges of Abraxane® patents

Share

Celgene prevails in Apotex and Cipla IPR challenges of Abraxane® patents

July 2018

Client(s) Celgene Corporation

Jones Day served as lead counsel and successfully defended Celgene Corporation in connection with six inter partes review (IPR) petitions filed by Apotex or Cipla against U.S. Patent Nos. 8,138,229, 7,820,788, and 7,923,536, which are related to formulations for Celgene's chemotherapeutic drug marketed as Abraxane®. Following the filing of the Patent Owner's Preliminary Response by Celgene, the Patent Trial and Appeal Board (PTAB) denied institution of all six IPR petitions with regard to all of the challenged claims.

Apotex Inc., et al. v. Abraxis Bioscience, LLC, et al., IPR Nos. 2018-00151, -00152, -00153 (PTAB); Cipla Limited, et al. v. Abraxis Bioscience, LLC, et al., IPR Nos. 2018-00162, -00163, -00164 (PTAB)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.